Graham Collins
LightNews LightNews
graham74gc.bsky.social
Graham Collins
@graham74gc.bsky.social
260 followers 43 following 77 posts
Lymphoma doctor and associate professor of Haematology at Oxford University Hospitals, UK. Husband, father, Christian.
Posts Replies Media Videos
graham74gc.bsky.social
Fujimoto et al - Allo / auto in ENKT? Japanese data.
• if in CR, ASCT appear superior to allo
• if in PR, allo appears preferable
• no impact on source of allo cells
I normally allo these pts in CR1 so potentially practise changing.
#18ICML #ICML25 #lymsm
June 20, 2025 at 8:28 AM
graham74gc.bsky.social
Held et al - NIVEAU trial. Nivo-GemOx vs GemOx RR PTCL
• 76 pts part of bigger trial
• PFS no diff but was ⬆️ when MVA performed
• responses ⬆️
• BUT ⬆️ toxic incl ‘infn’ (?hyperinfl state instead); ⬆️ deaths.
Doubt there will be further development.
#18ICML #ICML25 #lymsm
June 20, 2025 at 8:16 AM
graham74gc.bsky.social
Patel: JNJ4496 (anti CD19/20 tandem CAR) RR DLBCL, 41BB costim
• global Ph 1B
• med age 72y
• at RP2D, ORR 100%, CRR 80%
• no G3+ CRS, 8% ICANs
Very impressive results
#18ICML #ICML25 #lymsm
June 20, 2025 at 4:49 AM
graham74gc.bsky.social
Dreyfuss et al
• ISRT & Pembro in localised relapsed cHL
• RT dose varied according to response to Pembro
• generally safe & good outcomes
• did not seem to impair subseq Rx
Consider for older relapsed pts
#18ICML #ICML25 #lymsm
June 19, 2025 at 4:11 PM
graham74gc.bsky.social
Dreyfuss et al
• ISRT & Pembro in localised relapsed cHL
• RT dose varied according to response to Pembro
• generally safe & good outcomes
• did not seem to impair subseq Rx
Consider for older relapsed pts
#18ICML #ICML25 #lymsm
June 19, 2025 at 4:00 PM
graham74gc.bsky.social
Davison et al - PRO substudy of S1826 substudy. Interesting outputs:
• NivoAVD showed more fatigued compared with BV-AVD on treatment but did not meet ‘clin significant’ threshold.
• BV-AVD showed excess neuropathy which had a clinically meaningful impact.
#ICML25 #lymsm
June 19, 2025 at 3:39 PM
graham74gc.bsky.social
Evans et al: E-HIPI prognostic score early cHL
• Holistic consortium
• 1 binary factor: female sex better prog
• 3 continuous: max tumour diam, Hb and albumin. Great work from

Online calculator now available!
#18ICML #ICML25 #lyms
June 19, 2025 at 3:30 PM
graham74gc.bsky.social
Great work by @ABarrettHaem. NHSE data, older #Hodgkin pts. Outcomes ⬆️ with dox. Clearly may reflect selection, but interesting assocn seen between regional difference in dox use and outcome.

Take home message: if safe to use dox then do use it!

#18ICML #ICML25 #lymsm
June 19, 2025 at 2:21 PM
graham74gc.bsky.social
Lewis et al - MRD analysis in ENRICH: IR vs R-chemo in 1L MCL
• flow cytometry based
• MRD- most rapid with BR
• with RCHOP, even MRD- pts do poorly
• with IR, no assocn with MRD & outcome
#18ICML #ICML25 #lymsm
June 19, 2025 at 2:16 PM
graham74gc.bsky.social
Flerlage et al
• GLOW data nod LPHL
• completely resected 1A, RT assoc with ⬆️ PFS compared with observation
• unresected - ABVD-RT & RT do v well
• no infield relapses if RT given
Great work which significantly informs practice. #18ICML #ICML25
#lymsm
June 19, 2025 at 9:59 AM
graham74gc.bsky.social
Rossi et al - baseline MTV, Dmax & esp combo, assoc with PFS.
Independent effect of IPSS.
Both factors improve prognostic impact of iPET.
Based on AHL2011 study so all have 2x eacBEACOPDac as 1st 2 cycle.
#18ICML #ICML25
June 19, 2025 at 9:41 AM
graham74gc.bsky.social
Herrera et al - ctDNA in S1826
• 97% ctDNA + baseline
• clearance at C3D1 assoc with PFS
• within pos pts, those with minor ⬇️ assoc with esp poor outcomes
• EOT ctDNA detection also assoc with poor outcomes
CtDNA ripe for response adapted trials.
#18ICML #ICML25 #lymsm
June 19, 2025 at 9:29 AM
graham74gc.bsky.social
Ahmed et al - EBV & cHL subtype in S1826 study
• EBV+ pts do much better with NAVD compared with BV-AVD (EBV- also do better but less marked)
• non-NS histology also benefited more from NAVD.
Biology is important!
#lymsm #18ICML #ICML25
June 19, 2025 at 9:12 AM
graham74gc.bsky.social
Things are hotting up for the first of 2 #Hodgkin lymphoma sessions today.
#18ICML #ICML25 #lymsm
June 19, 2025 at 8:54 AM
graham74gc.bsky.social
A no. of trials in RR DLBCL with RGemOx as comparator all show:
• PFS med 2-3 mo
• OS med 12-13 mo
Well known tox of neutropenia, PN, fatigue, thrombocytopenia etc.

Beaten by exptl arms in StarGlo, Polargo, Sunmo

Take home: no more RGemOx pls - it’s defeated!
#18ICML #lymsm
June 18, 2025 at 9:13 PM
graham74gc.bsky.social
Feldman et al - acimtamig (CD16/CD30 engager) with alloNK in RR #Hodgkin
• 24 pts, heavily preRx
• ORR 88%, CRR 58%
• 25% CRS with 1 G3, no ICANs or GvH
Looks very active. Interested to see how it will developed further.
#18ICML
June 18, 2025 at 4:05 PM
graham74gc.bsky.social
Shah et al - Zamto-cel 3L+ DLBCL
• tandem CD19 / CD20 41BB construct
• non cryopreserved, short vein-vein
• 69 pts
• ORR 73%, CRR 51%
• no G3+ CRS, 4% G3+ ICANS
Clearly active but is it better than current agents?
#18ICML
June 18, 2025 at 3:43 PM
graham74gc.bsky.social
Sancho et al - POLARGO.
• RGemOx vs Pola-RGemOx R/R DLBCL
• 2L+ DLBCL (no ASCT eligible if 2L)
• OS primary EP: signif adv 12.5mo vs 19.5mo
• PFS & CMR rate better
• tox modest - ⬆️ infn & PN
• no effect of cell of origin
Interesting but ? value if 1L PolaRCHP
#18ICML
June 18, 2025 at 1:14 PM
graham74gc.bsky.social
Stathis et al - feasibility of PET & ctDNA response adaptation in 1L DLBCL.
• operationally deliverable with ctDNA turnaround median 9d
• low rate PET+ and ctDNA+ at interim
• assessing whether acala addition benefits those with Myd88 &/or CD79b mutns
SAKK38/19 trial #ICML18
June 18, 2025 at 12:50 PM
graham74gc.bsky.social
@dgermain21.bsky.social - fantastic work on LymphomaMAPs (microenv of DLBCL) looking at prognosis of CAR-T therapy. Showed that TEX archetype associated with signif worse outcome. Assoc with
• exhausted T-cells
• super-activated macrophages.
#ICML18
June 18, 2025 at 12:18 PM
graham74gc.bsky.social
It’s the unboxing of the eighth edition of Hoffbrands Postgraduate Haematology. A real honour to be an editor alongside Adam Mead, Deborah Hay, Mike Lanffan and of course Victor Hoffbrand. Do get your copy!
May 13, 2025 at 6:22 PM
graham74gc.bsky.social
Delighted to be sharing the stage with the great @broeckelmann.bsky.social at the 10th International Congress on Leukemia, Lymphoma and Myeloma. An erudite overview of the 1L setting - I’ve been given relapsed disease. #lymsm
May 10, 2025 at 1:19 PM
graham74gc.bsky.social
Haynes et al - also data on bispecifics in secondary CNS lymphoma. 5/9 showed some response. #BSH2025 @bsochaem.bsky.social
April 27, 2025 at 3:53 PM
graham74gc.bsky.social
Update on UK real world bispecific data. ITT ORR 41% & CRR 22.2%. G3+ infn 29%.

PS, prior benda & refractory to last line assoc with worse outcome.

Clear that some very ill and heavily pretreated pts being given bispecifics in real world setting. Should they be?

#BSH2025 @bsochaem.bsky.social
April 27, 2025 at 3:51 PM
graham74gc.bsky.social
ENRICH study - fantastic data from UK study. De David Lewis.

IR superior PFS compared with 1L R-chemo with most benefit coming from RCHOP comparison. #BSH2025 @christianb.bsky.social
April 27, 2025 at 3:37 PM